Selincro (nalmefene) Tablets 10mg Receives Regulatory Approval in Japan

First Drug Approved in Japan to Reduce Alcohol Consumption in Alcohol-dependent Patients Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A / S of Denmark are pleased to announce that Otsuka has received regulatory approval in Japan for the manufacture and sale of Selincro Tablets 10 mg (generic name: nalmefene hydrochloride), a therapeutic drug treatment to reduce alcohol consumption in alcohol-dependent patients. In 2013 Otsuka formed an agreement with Lundbeck on the development and commercialization in Japan of Lundbeck's nalmefene.

The release as fetched from its publisher. otsuka.co.jp ↗